Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn More
Although there are drugs for the treatment of leukemia, the cure rate and recurrence of leukemia patients are still serious problems. The development of new leukemia drugs has become the focus of attention, in the discovery and verification of drug targets is the first step. The drug discovery solution provided by Alfa Cytology can solve the problem of the leukemia drug discovery process for you. We provide leukemia drug target discovery to target verification services to support your early drug discovery research.
There are often experimental failures, and, in most cases, only a small number of clinical trial drugs are approved. Therefore, researchers continue to develop new therapeutic drugs, and drug target identification and verification is an important step in drug discovery. To provide a new direction for the treatment of leukemia, it is helpful to identify new therapeutic targets and verify whether these targets can be used as potential therapeutic targets.
Fig. 1. Schematic of a focused RNAi screen for genes encoding known drug targets. ( Manchado, E. et al., 2016)
Target identification involves the process of discovering potential therapeutic targets of drugs or biologics, which is essential for drug discovery and development. Alfa Cytology provides various target identification services for leukemia, including but not limited to the following.
Based on our next-generation sequencing (NGS) technology, genetic changes such as gene mutations, gene fusions or chromosome abnormalities associated with leukemia can be identified. Through this information, we can find potential therapeutic targets for you.
Signaling Pathways Identification
In addition, we offer multi-omics analyses that utilize genomic, transcriptomic, proteomic, modified proteomic, metabolomic, and other combinatorial data to more accurately reveal leukemia signaling pathways and to identify the mechanism of action of reliable drugs on multiple levels.
Screening Drug Targets by Leukemia Models
We have a variety of leukemia models for drug target verification, such as genetically engineered mouse models, patient-derived xenotransplantation models, and leukemic cell lines. These models can be used to verify the functional importance of potential targets in vivo and to evaluate the effects of target regulation on the development, progression, and therapeutic response of leukemia.
Target Identification by RNAi
The RNAi technology we provide can introduce shRNA or cDNA into cells to knock down or over-express genes of interest. RNAi can be used to identify genes that inhibit the proliferation and viability of leukemic cells and is widely used to identify targets for new treatment of leukemia.
CRISPR Cas9 for Target Identification and Validation
The CRISPR technology we provide can accurately identify and validate targets of interest in leukemia. Our CRISPR technology identifies and verifies targets by introducing gene knockout and gene knockout and validating the effect of target knockout on living organisms. Compared with RNAi, CRISPR technology can eliminate gene expression and provide better interpretable results.
High Throughput Screening (HTS)
The high throughput screening was used to detect large-scale compounds or small interference RNA in leukemic cells to identify molecules that selectively inhibit the growth of leukemic cells or target specific pathways. The HTS we provide can help find new therapeutic targets or reuse existing drugs for leukemia treatment.
Alfa Cytology provides a variety of biological techniques for drug target identification and verification in leukemia. Our goal is to identify genes critical to the survival of leukemic cells for customers and may become potential therapeutic targets. We are happy to discuss with you how our services can add value to your plan and help your drug target identification and verification process succeed. If you are interested in our services or would like to know more, please contact us.
Reference
